Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

← catalyst calendar

NCT05059522 · readout in 134 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

77actual

Sites

Countries

Australia, Belgium, Canada +16

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2021-09-29

actual

When the study began enrolling

Primary completion

2026-12-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-12-31

estimated

The whole study's end, after follow-up

First posted

2021-09-28

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-22

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Advanced Malignancies
NSCLC
Ovarian Cancer
Urothelial Cancer
Solid Tumors

Interventions

Drug: Avelumab
Drug: Lorlatanib
Drug: Talazoparib
Drug: Pemetrexed
Drug: Axitinib
Drug: CMP 001
Drug: Utomilumab
Drug: PF04518600

Primary outcomes

what the primary-completion date above is the date OF

Number of participants with adverse events leading to permanent discontinuation of study intervention

measured Baseline up to approximately 5 years

Number serious adverse events reported for all participants

measured Baseline up to approximately 5 years

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed